AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24432675 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 22151676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen (50:50) self-administered until pain relief achieved (max 15 min)
Number of subjects: 100
Study 22151676 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 µg/kg) as a single dose
Number of subjects: 100
Study 19554988 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group discussion
Number of subjects: 51
Study 19554988 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 51
Study 16382319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU plus calcium 1 g daily
Number of subjects: 40
Study 16382319 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 40
Study 15248630 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral paravertebral blockade combined with general anaesthesia (active)
Number of subjects: 60
Study 10886045 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine bismuth citrate 400 mg b.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (RCM)
Number of subjects: 210
Study 10886045 — intervention group
Group type: EXPERIMENTAL
Intervention: bismuth subcitrate 240 mg b.d. + amoxycillin 1000 mg b.d. + metronidazole 500 mg b.d. (BAM)
Number of subjects: 210
Study 10886045 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg o.d. + clarithromycin 250 mg b.d. + metronidazole 500 mg b.d. (OCM)
Number of subjects: 210
Study 10886045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall resistant strains
Number of subjects: 210
Study 10886045 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity to both antibiotics
Number of subjects: 210
Study 9076205 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas
Number of subjects: 514
Study 9076205 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil
Number of subjects: 514
Study 9076205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-treated eyes
Number of subjects: 514
Study 9076205 — intervention group
Group type: COMPARATOR
Intervention: Silicone oil-treated eyes
Number of subjects: 514
Study 9076205 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-removed eyes
Number of subjects: 514
Study 8322031 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 32
Study 8322031 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxindanac
Number of subjects: 32
Study 8322031 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 32
Study 2950915 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream and shampoo
Number of subjects: 20
Study 2950915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29074043 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in lymphocyte to neutrophil ratio (ΔLNR)
Number of subjects: 74
Study 29074043 — intervention group
Group type: EXPERIMENTAL
Intervention: LNR at baseline and at 3, 6, and 12 months
Number of subjects: 74
Study 29074043 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the curve of ΔLNR for acute rejection
Number of subjects: 74
Study 29074043 — intervention group
Group type: EXPERIMENTAL
Intervention: Best cutoff value of ΔLNR
Number of subjects: 74
Study 27438344 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 1000
Study 25555593 — intervention group
Group type: EXPERIMENTAL
Intervention: Wufuxinnaoqing Soft Capsule (WSC)
Number of subjects: 240
Study 25555593 — intervention group
Group type: COMPARATOR
Intervention: Control (WSC mimetic)
Number of subjects: 240
Study 23988379 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous idursulfase 0.5 mg/kg weekly for two years
Number of subjects: 63
Study 20227099 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition (immune-enhancing diets enriched with arginine, omega-3 fatty acids, and RNA for 5 days before and after surgery)
Number of subjects: 30
Study 20227099 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative immunonutrition
Number of subjects: 30
Study 20227099 — intervention group
Group type: COMPARATOR
Intervention: Postoperative enteral infusion of the same enriched formula
Number of subjects: 30
Study 20227099 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition
Number of subjects: 30
Study 18098274 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A
Number of subjects: 111
Study 18098274 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐B
Number of subjects: 111
Study 16049264 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-centered, ecodevelopmental HIV preventive intervention
Number of subjects: 91
Study 16049264 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-facilitator relationship quality
Number of subjects: 91
Study 16049264 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cohesion
Number of subjects: 91
Study 13677272 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine (0.1 R)
Number of subjects: 56
Study 13677272 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (0.2 R)
Number of subjects: 56
Study 13677272 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine (0.125 B)
Number of subjects: 56
Study 10372954 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose physostigmine infusion (1-1.5 mg over 45-60 min)
Number of subjects: 9
Study 10372954 — intervention group
Group type: COMPARATOR
Intervention: Chronic physostigmine administration (2-12 mg/day)
Number of subjects: 9
Study 10372954 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (cognition-enhancing doses)
Number of subjects: 9
Study 9304934 — intervention group
Group type: COMPARATOR
Intervention: Surgical instruments covered with dressing
Number of subjects: 0
Study 9304934 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical instruments exposed to air
Number of subjects: 0
Study 2053197 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg 17 beta‐oestradiol
Number of subjects: 28
Study 2053197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6354030 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 62
Study 6354030 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 62
Study 29679919 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone administration
Number of subjects: 50
Study 27333588 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month (PP3M) formulation
Number of subjects: 0
Study 27333588 — intervention group
Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month (PP1M) formulation
Number of subjects: 0
Study 25027585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (2 mg daily for 12 weeks)
Number of subjects: 26
Study 25027585 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg daily for 12 weeks)
Number of subjects: 26
Study 25027585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 26
Study 22808721 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% feedback frequency
Number of subjects: 19
Study 22808721 — intervention group
Group type: COMPARATOR
Intervention: 62% faded feedback frequency
Number of subjects: 19
Study 20831683 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 50 mg/m2
Number of subjects: 22
Study 18619812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 33
Study 18619812 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 33
Study 18619812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors and atypical antipsychotics
Number of subjects: 33
Study 15890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased social activities or satisfaction
Number of subjects: 44
Study 15890493 — intervention group
Group type: COMPARATOR
Intervention: Disruptions in social relations
Number of subjects: 44
Study 15890493 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive changes in social relations
Number of subjects: 44
Study 14571154 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg
Number of subjects: 44
Study 14571154 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg
Number of subjects: 44
Study 11220983 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented by Lactobacillus casei (10(8) cfu/ml)
Number of subjects: 928
Study 11220983 — intervention group
Group type: COMPARATOR
Intervention: Standard yogurt
Number of subjects: 928
Study 8818493 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound examination
Number of subjects: 43
Study 8818493 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal population)
Number of subjects: 43
Study 1433774 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 70
Study 1433774 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent position
Number of subjects: 70
Study 1433774 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NGT
Number of subjects: 70
Study 1433774 — intervention group
Group type: COMPARATOR
Intervention: Patients without NGT
Number of subjects: 70
Study 3893598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 100
Study 3893598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 3893598 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance clinic
Number of subjects: 100
Study 29787409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 60
Study 29787409 — intervention group
Group type: COMPARATOR
Intervention: Palpation group
Number of subjects: 60
Study 29898344 — intervention group
Group type: EXPERIMENTAL
Intervention: Care based on Swanson's theory of caring
Number of subjects: 43
Study 29898344 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 43
Study 27248467 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 14
Study 27248467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27248467 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT
Number of subjects: 14
Study 24233282 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline depression (BDI-II score > 13)
Number of subjects: 201
Study 24233282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower executive function
Number of subjects: 201
Study 24233282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower memory performance
Number of subjects: 201
Study 24233282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretransplant depression and anxiety
Number of subjects: 201
Study 21349594 — intervention group
Group type: COMPARATOR
Intervention: 5 mg rosuvastatin
Number of subjects: 87
Study 21349594 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin
Number of subjects: 87
Study 19926203 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Optical Access (DOA)
Number of subjects: 194
Study 19926203 — intervention group
Group type: COMPARATOR
Intervention: Verres needle (classical closed method)
Number of subjects: 194
Study 17334952 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational campaign regarding stroke knowledge
Number of subjects: 422
Study 17334952 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic factors (age, sex, education)
Number of subjects: 422
Study 15757856 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose FSH (375 IU) during the early follicular phase (group A)
Number of subjects: 0
Study 15757856 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 consecutive low doses FSH (75 IU/day) starting in the mid follicular phase (group B)
Number of subjects: 0
Study 15757856 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low doses FSH (75 IU/day) during the early to late follicular phase (groups C, D, E)
Number of subjects: 0
Study 15757856 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle (control)
Number of subjects: 0
Study 10683601 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione supplementation (200 mg daily for 2 days)
Number of subjects: 10
Study 10683601 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione supplementation with heavy resistance exercise
Number of subjects: 10
Study 10683601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 9587536 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination group: 3 i.m. injections of GenHevac B followed by one booster at month 9
Number of subjects: 25
Study 9587536 — intervention group
Group type: COMPARATOR
Intervention: Serovaccination group: same vaccination schedule followed by one i.m. injection of anti‐HBs immunoglobulins (500 IU)
Number of subjects: 25
Study 8314383 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AGT) 125 mg twice daily
Number of subjects: 56
Study 8314383 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone (HC) 20 mg twice daily
Number of subjects: 56
Study 3492816 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic-disease data-bank system
Number of subjects: 0
Study 30103792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated screw locking plate (CSLP)
Number of subjects: 68
Study 30103792 — intervention group
Group type: COMPARATOR
Intervention: Multiple cancellous screws (MCS)
Number of subjects: 68
Study 26791936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster sets of 2 (CS2)
Number of subjects: 12
Study 26791936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster sets of 4 (CS4)
Number of subjects: 12
Study 26791936 — intervention group
Group type: COMPARATOR
Intervention: Traditional sets (TS)
Number of subjects: 12
Study 23731911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists (rotigotine or cabergoline)
Number of subjects: 40
Study 23731911 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 40
Study 23731911 — intervention group
Group type: COMPARATOR
Intervention: Off therapy
Number of subjects: 40
Study 21424279 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive, moderate-intensity resistance + impact training
Number of subjects: 106
Study 18504322 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake-restricted weight loss (n=26)
Number of subjects: 40
Study 18504322 — intervention group
Group type: COMPARATOR
Intervention: Attention control (n=14)
Number of subjects: 40
Study 16996879 — intervention group
Group type: EXPERIMENTAL
Intervention: LIGHT (40% of maximal oxygen consumption)
Number of subjects: 50
Study 16996879 — intervention group
Group type: EXPERIMENTAL
Intervention: MODERATE (60% of maximal oxygen consumption)
Number of subjects: 50
Study 16996879 — intervention group
Group type: COMPARATOR
Intervention: nonexercise control
Number of subjects: 50
Study 12599025 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery without drainage in pancreatic resections
Number of subjects: 0
Study 12599025 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding drainages in colorectal surgery
Number of subjects: 0
Study 12599025 — intervention group
Group type: COMPARATOR
Intervention: Use of drainages in perforated appendicitis
Number of subjects: 0
Study 10743984 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical pathway (levofloxacin treatment)
Number of subjects: 1743
Study 10743984 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1743
Study 9406110 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1548352 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (10 mg/day)
Number of subjects: 15
Study 1548352 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 15
Study 3771813 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 640 mg/day
Number of subjects: 13
Study 29789302 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 196
Study 29789302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 27543797 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-719 800 μg/kg
Number of subjects: 240
Study 27543797 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-719 1600 μg/kg
Number of subjects: 240
Study 27543797 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-719 2100 μg/kg
Number of subjects: 240
Study 27543797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 24987970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue application
Number of subjects: 26
Study 21737704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g bolus before incision, 400 mg/h infusion during surgery)
Number of subjects: 231
Study 21737704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 231
Study 21737704 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution infusion)
Number of subjects: 231
Study 20164695 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin/etoposide (PCE)
Number of subjects: 198
Study 20164695 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/irinotecan
Number of subjects: 198
Study 18217908 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily cyclosporine dosing (group B)
Number of subjects: 60
Study 18217908 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily cyclosporine dosing with 25% dose reduction (group C)
Number of subjects: 60
Study 18217908 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily cyclosporine dosing (group A)
Number of subjects: 60
Study 18217908 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to once-daily dosing
Number of subjects: 60
Study 19880675 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-681323 7.5 mg
Number of subjects: 17
Study 19880675 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-681323 25 mg
Number of subjects: 17
Study 19880675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg
Number of subjects: 17
Study 19880675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 10 mg
Number of subjects: 17
Study 19880675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16314594 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained physicians in communication skills
Number of subjects: 1785
Study 16314594 — intervention group
Group type: COMPARATOR
Intervention: Untrained physicians
Number of subjects: 1785
Study 16314594 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions of 'uncertainty'
Number of subjects: 1785
Study 16314594 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness perceptions of 'emotional representations'
Number of subjects: 1785
Study 11903939 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline)
Number of subjects: 44
Study 11903939 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) morphine (0.1 mg x kg(‐1) i.v. immediately after intubation, with postoperative bolus doses of 0.5 mg, 1 mg, or 1.5 mg based on weight)
Number of subjects: 44
Study 11903939 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 44
Study 11903939 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (Epidural and PCA)
Number of subjects: 44
Study 11903939 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 44
Study 9783498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/d for 12 weeks, increased to 10 mg/d if DBP >= 95 mm Hg after 4 weeks)
Number of subjects: 60
Study 9783498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (5 mg/d)
Number of subjects: 60
Study 9783498 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2-week run-in period)
Number of subjects: 60
Study 7940622 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral message linking family planning and EPI services
Number of subjects: 0
Study 3665118 — intervention group
Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery for large non‐functioning pituitary tumours
Number of subjects: 58
Study 3665118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐operative bromocriptine therapy
Number of subjects: 58
Study 3665118 — intervention group
Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery for non‐invasive macroprolactinomas
Number of subjects: 58
Study 3665118 — intervention group
Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery for meso‐prolactinomas and microprolactinomas
Number of subjects: 58
Study 3665118 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐operative bromocriptine therapy for macroprolactinomas
Number of subjects: 58
Study 3665118 — intervention group
Group type: COMPARATOR
Intervention: Surgery vs. radiotherapy for invasive prolactinomas and macroprolactinomas with uneven shrinkage
Number of subjects: 58
Study 3665118 — intervention group
Group type: COMPARATOR
Intervention: Surgery for microprolactinomas
Number of subjects: 58
Study 31342245 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofilament and synthetic sutures
Number of subjects: 32
Study 31342245 — intervention group
Group type: EXPERIMENTAL
Intervention: All sutures
Number of subjects: 32
Study 31342245 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-resorbable polypropylene suture
Number of subjects: 32
Study 31342245 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-resorbable silk suture
Number of subjects: 32
Study 28627254 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month lifestyle physical activity intervention
Number of subjects: 60
Study 28627254 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 25947264 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg of oral paracetamol, 60 min before examination
Number of subjects: 114
Study 23995795 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB) treatment
Number of subjects: 12
Study 22524633 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal group (ERG)
Number of subjects: 205